Comments: NJ A3793 | 2016-2017 | Regular Session

Bill Title: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Spectrum: Slight Partisan Bill (Democrat 6-2)

Status: (Introduced - Dead) 2016-10-20 - Substituted by S2024 [A3793 Detail]

Text: Latest bill text (Introduced) [HTML]

PolitiCorps Conversations

Start PolitiCorps Debate
TitlePolitiCorpsAccessCommentsViewsLast Post
There are no visible public or private PolitiCorps discussions concerning the 2016 New Jersey A3793 at this time.

Social Comments on NJ A3793

feedback